Trial Title:
Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment
NCT ID:
NCT06374485
Condition:
Advanced Hepatocellular Carcinoma
Conditions: Official terms:
Carcinoma
Carcinoma, Hepatocellular
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
AU409 capsules
Description:
Oral administration
Arm group label:
AU409
Summary:
This study is a Phase I, dose-escalation study of AU409 in advanced hepatocellular
carcinoma patients who failed standard treatment. A '3+3' dose-escalation design will be
utilized to gradually increase the dose of AU409, aiming to assess the safety,
tolerability, pharmacokinetics, and preliminary antitumor efficacy of multi-dose AU409 in
patients with advanced HCC.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Male or female of 18-75 (inclusive) years of age.
2. Patients with histologically and/or cytologically and/or radiologically confirmed
advanced (unresectable or metastatic) hepatocellular carcinoma (HCC) that have
failed any of standard treatment (including Immunotherapies and/or Tyrosine Kinase
Inhibitor therapies, or Oxaliplatin-based systemic chemotherapies), recurrence, or
are intolerant.
3. Before treatment initiation, patients must have previously completed chemotherapy,
radiotherapy, interventional therapy for more than 4 weeks (except palliative
radiotherapy for bone metastasis). And all treatment-related toxicities (except hair
loss, pigmentation, and chemotherapy-related neurotoxicities, etc.) have recovered
(≤ level 1 or baseline level).
4. Have at least one evaluable disease lesion based on the modified Response Evaluation
Criteria in Solid Tumors (mRECIST).
5. ECOG score of 0 or 1.
6. Patients with Child Pugh class A or some class B (≤7 and no hepatic encephalopathy).
7. Have a life expectancy of >12 weeks.
8. Able to be orally administered.
9. Laboratory examinations must meet the following criteria within 7 days before
treatment initiation:
- Absolute neutrophil count（ANC）≥1.5 × 109/L，platelets（PLT） count ≥75 ×
109/L，hemoglobin（HGB）≥90 g/L，and patients are not allowed to receive blood
transfusion or other haematopoietic growth factors within 14 days before
treatment initiation.
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be
≤5.0×upper limit of normal (ULN).
- Total bilirubin (TBIL) ≤1.5×ULN.
- Ablumin (ALB) ≥28g/L.
- Serum creatinine (CRE) ≤1.0×ULN, creatinine clearance rate (CCR) ≥60 mL/min
(Cockcroft-Gault equation).
- International normalized ratio（INR）≤1.5，prothrombin time (PT) ≤1.5×ULN.
10. Have a negative serum pregnancy test for premenopausal women (postmenopausal women
who have been menopausal for at least 12 months are considered as infertile). For
male patients (including male patients' female spouses of child-bearing potential)
and female patients of child-bearing potential must be contraceptive throughout the
study and within the 6 months following the last dose of AU409.
11. Patients voluntarily give written informed consent form (ICF).
Exclusion Criteria:
1. Patients of central nervous system metastasis with clinical symptoms (except
patients who are asymptomatic, and no disease progression confirmed by MRI diagnosis
for more than 28 days).
2. Allergies to any ingredients or excipients in AU409.
3. Treatment with other anticancer therapies (including surgery, radiation therapy,
chemotherapy, anti-angiogenic therapy, targeted therapy, or radiofrequency ablation
therapy, etc.) or investigational therapy (except patients who stop treatment of
Chinese patent medicine or Chinese herbal medicine for more than 7 days, or complete
palliative radiotherapy for bone metastasis >2 weeks) within 28 days prior to the
first dosing.
4. QTc ≥470 msec during screening period (Fridericia's equation) or with a history of
congenital long QT syndrome.
5. Patients with history of gastrointestinal surgery that may change the absorption and
activity of drugs in their body (such as total gastrectomy, small bowel resection,
external bile shunt, etc.) in combination with refractory hiccups, nausea, vomiting,
and other diseases that affect drug absorption (such as peptic ulcer, inflammatory
bowel disease, lactose intolerance, malabsorption syndrome or chronic diarrhea,
etc.).
6. Patients who require serous effusion for continuous drainage or drug infusion (such
as ascites, pleural effusion, etc.), or have undergone portal vein shunt.
7. Patients with gastrointestinal perforation and/or fistula, abdominal abscess,
visceral fistula, intestinal obstruction, hepatic encephalopathy, portal vein and
inferior vena cava cancer thrombus within 3 months prior to the treatment
initiation.
8. Patients have gastrointestinal bleeding (including esophageal or gastric varices,
local active ulcer lesions, etc.), or have a clear bleeding tendency, or are
receiving anticoagulation/thrombolytic therapy within 3 months before treatment
initiation. Positive result of occult blood needs to identifythe causes.
9. Patients with interstitial lung disease, non-infectious pneumonia.
10. History of allogeneic stem cell transplantation or organ transplantation.
11. Patients who receive major surgery (except biopsy and puncture) or with major trauma
within 28 days before treatment initiation.
12. Patients with infectious diseases that affect daily activities or require systemic
treatment (such as the use of hormones, antibiotics, antifungal drugs, antiviral
drugs, and oxygen inhalation), including but not limited to infections requiring
hospitalization, bacteremia, severe pneumonia, etc.
13. Uncontrolled diseases, including a) New York Heart Association (NYHA) Class II or
higher heart failure, b) Severe/unstable angina pectoris, c) Primary cardiomyopathy,
d) Myocardial infarction or coronary/peripheral artery bypass surgery occurred
within 6 months before treatment initiation, e) Uncontrollable high blood pressure,
f) Severe arrhythmia requiring medication or intervention, g) Echocardiographic left
ventricular ejection fraction <50% during the screening period, h) Deep vein
thrombosis/arterial thrombosis /Pulmonary vein embolism occurred within 2 months
before treatment initiation, i) Cerebrovascular accident or transient ischemic
attack occurred within 6 months before treatment initiation, j) Ocular lens disease
(such as cataract), k) Diabetes that has not been effectively controlled, l) Thyroid
diseases that have not been effectively controlled, m) Urine protein≥2+ and quantity
of 24-hour urine protein ≥1.0g.
14. Human immunodeficiency virus infection (HIV 1/2 antibody positive).
15. HBV infection (HBsAg positive and HBV DNA ≥2000 IU/mL); Hepatitis C virus (HCV)
antibody is positive and HCV RNA>103 copies/ml; HBsAg and HCV antibodies are both
positive.
16. Patients with tuberculosis (TB) who need to receive/are receiving anti-TB treatment
within 1 year before treatment initiation.
17. Pregnant or nursing；
18. Patients complicated with other malignant tumors within 5 years before treatment
initiation, except various in situ tumors, skin basal cell carcinoma or squamous
cell carcinoma that have been cured in the past, local prostate cancer receiving
radical operation, and in situ breast ductal carcinoma receiving radical operation.
19. Patients with other severe, acute, chronic, or psychiatric illnesses that may
increase the risk of treatment or may interfere with interpretation of the trial
results. And patients with alcoholism, smoking addiction, drug abuse, and other
circumstances that are not conductive to the treatment or explain adverse events,
thereby contributing to decrease study compliance.
20. Other conditions that are not suitable for participating in the study in the opinion
of investigator.
21. Patients who were treated with pentamidine prior to treatment initiation or during
the study.
Gender:
All
Minimum age:
18 Years
Maximum age:
75 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Department of Clinical Oncology, Queen Mary Hospital
Address:
City:
Hong Kong
Country:
China
Status:
Recruiting
Investigator:
Last name:
Chi Leung Chiang
Email:
Principal Investigator
Investigator:
Last name:
Albert Chan
Email:
Sub-Investigator
Investigator:
Last name:
Aya El HELALI
Email:
Sub-Investigator
Start date:
April 12, 2024
Completion date:
August 28, 2026
Lead sponsor:
Agency:
Lee's Pharmaceutical Limited
Agency class:
Industry
Source:
Lee's Pharmaceutical Limited
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06374485
